Leukemia Clinical Trials in Philadelphia

Showing 301-320 of 1,308 trials

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

NCT06934382

This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.

T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Stephan Grupp MD PhD33 participantsStarted Apr 2025

Philadelphia, Pennsylvania, United States

RECRUITINGPhase 1/2< 1 mile

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

NCT05480449

This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acute Lymphoblastic Leukemia (B-ALL).

B Cell Acute Lymphoblastic Leukemia (B-ALL)B Lineage Lymphoblastic Lymphoma

Stephan Grupp MD PhD89 participantsStarted Sep 2022

Philadelphia, Pennsylvania, United States

RECRUITINGPhase 1/2< 1 mile

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT04068597

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

Haematological MalignancyAcute Myeloid LeukemiaNon Hodgkin Lymphoma+3 more

CellCentric Ltd.250 participantsStarted Aug 2019

Atlanta, Georgia, United States • Indianapolis, Indiana, United States • Bethesda, Maryland, United States +36 more locations

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Leukemia Trials in Other Cities

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Study of Oral Food Challenge Biomarkers (SAFER)

UNITY VCS Vitreoretinal Surgery

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

Other Conditions in Philadelphia